Global Tenofovir Disoproxil Share Report 2025, Forecast To 2034
26 Mar, 2025
What are the Historical Developments and Current Growth Metrics of the Tenofovir Disoproxil Market?
The tenofovir disoproxil market has seen considerable growth due to a variety of factors.
• In the past few years, there has been significant growth in the tenofovir disoproxil market size. The market is projected to increase from $3.58 billion in 2024 to $3.79 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%.
This growth in the historical period can be associated with factors such as increased awareness and early diagnosis of viral infections, a rise in hepatitis b infections, an expansion in the generic drug manufacturing for tenofovir disoproxil, a rise in clinical trials verifying the efficacy of tenofovir, and growth in funding for infectious disease treatment in the health sector.
What Does Future Hold for The Tenofovir Disoproxil Market By 2029?
The tenofovir disoproxil market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, a robust growth is expected in the market size of tenofovir disoproxil, predicted to reach $4.72 billion in 2029 with a compound annual growth rate (CAGR) of 5.6%.
The upward trend during the forecast period is credited to factors such as increased demand for sustained-release formulations of tenofovir, emphasis on combination therapies with newer antivirals, increasing regulatory endorsements for innovative tenofovir combinations, heightened focus on tenofovir pediatric formulations, and the escalating need for tenofovir in post-exposure prophylaxis. Noteworthy trends for the evaluation period comprise development of innovative drug delivery systems, adoption of artificial intelligence in drug development, progress in combination therapies, advancements in nanotechnology-based delivery, and progress in fixed-dose combination therapies.
What Are The Primary Growth Drivers In The Tenofovir Disoproxil Market?
The escalating occurrence of HIV and AIDS is predicted to fuel the expansion of the tenofovir disoproxil market in the future. HIV and AIDS, a chronic viral illness, debilitates the immune system by targeting CD4 cells, thus making the body susceptible to other infections and diseases. Factors like unprotected sex, insufficient awareness, limited healthcare access, and drug-resistant viral strains contribute to the rising prevalence of HIV and AIDS. As tenofovir disoproxil is a crucial antiretroviral medicine used for treatment and prevention, this heightened prevalence is creating a greater demand for it. A report from the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Swiss Government entity, in July 2024 verified that approximately 39.5 million individuals were globally HIV-positive by the end of 2022, that year reporting about 1.3 million new infections. Roughly 630,000 global deaths from AIDS-related conditions were recorded in 2022. An estimated 39.9 million (range 36.1 million–44.6 million) people had HIV in 2023. Thus, the augmented prevalence HIV and AIDS bolster the growth of the tenofovir disoproxil market. The surging frequency of hepatitis B could also stimulate the growth of the tenofovir disoproxil market in the future. A viral infection, hepatitis B, targets the liver, which could result in both acute and chronic conditions. It spreads via contact with infected blood or bodily secretions. The escalating rate of hepatitis B is a result of causes such as perinatal transmission, unsafe medical procedures, inadequate vaccination coverage, and continued chronic infections in impacted communities. Tenofovir disoproxil is utilized to manage chronic hepatitis B by curtailing viral multiplication and mitigating liver injury. A report from the Centers for Disease Control and Prevention, a US government public health agency, in March 2023 highlighted that around 580,000 to 2.4 million individuals in the United States were living with hepatitis B, with approximately two-thirds potentially ignorant about their infection. Thus, the increased occurrence of hepatitis B stimulates the expansion of the tenofovir disoproxil market.
What Is The Segmentation Of The Global Tenofovir Disoproxil Market?
The tenofovir disoproxil market covered in this report is segmented –
1) By Type: Tablet, Powder
2) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Wholesalers Or Distributors
3) By Application: Hospital, Clinic
Subsegments:
1) By Tablet: Single-Drug Tablets, Fixed-Dose Combination Tablets
2) By Powder: Oral Powder, Reconstitutable Powder
What Trends Are Reshaping The Future Of The Tenofovir Disoproxil Market?
Key players in the tenofovir disoproxil market are focusing their efforts on innovating new formulations, such as combination therapy, in order to bolster their competitive standing and improve the treatment of HIV/AIDS. The term combination therapy refers to the simultaneous application of two or more treatments, frequently drugs, with the aim of enhancing efficacy and improving patient outcomes for specific conditions. As an example, in July 2022, Gilead Sciences Inc., a biopharmaceutical company based in the USA, revealed that the U.S. Food and Drug Administration (FDA) approved their product, Vemlidy (tenofovir alafenamide), for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients. This applies to those who are six years and older, weigh a minimum of 25 kilograms, and have compensated liver disease. The FDA's approval of Vemlidy for this particular age group was underpinned by results from a Phase II clinical trial, which demonstrated the drug's safety and effectiveness in children as young as six years old.
Who Are the Key Players In The Tenofovir Disoproxil Market?
Major companies operating in the tenofovir disoproxil market are:
• Gilead Sciences Inc.
• Viatris Inc.
• Teva Pharmaceuticals Limited
• Cipla Ltd
• Lupin Limited
• Mylan NV
• Blanver
• SMS Pharmaceuticals
• Bajaj Healthcare
• Mangalam Drugs & Organics Ltd
• Nortec Quimica
• Arene Lifesciences
• Cdymax
• HRV Global Life Sciences
• Pipelinepharma
• Qilu Pharmaceutical
• Jai Radhe Sales
• Sinoway Industrial Co. Ltd
• Aurisco Pharmaceutical
• Huangshi Fuertai Pharmaceutical Tech Co. Ltd
What Are The Regional Insights Into The Tenofovir Disoproxil Market?
North America was the largest region in the tenofovir disoproxil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tenofovir disoproxil market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.